Parsortix Released to Research Partners

RNS Number : 7461T

Angle PLC

18 December 2012

 



For immediate release

18 December 2012

ANGLE plc

("ANGLE" or "the Company")

PARSORTIX SEPARATION SYSTEM RELEASED TO RESEARCH PARTNERS   

ANGLE plc (AIM: AGL), the specialist medtech company, is pleased to announce that it has released its Parsortix non-invasive cancer diagnostic product to its research partners. 

ANGLE's patent-protected Parsortix technology enables the simple and effective capture and counting of very rare circulating tumour cells (CTCs) from cancer patient blood ("blood separations"). 

ANGLE's Parsortix system comprises an automated machine for running blood separations (the "MK1 machine") and a separation cassette (the "GEN3 cassette"), which is a consumable running on the MK1 machine. 

ANGLE has established long term partnership arrangements with two research partners:

·     the Cancer Research UK-funded Paterson Institute for Cancer Research, The University of Manchester's world-leading cancer research institute; and

·     the University of Surrey's Oncology Department, which works alongside the Royal Surrey Hospital and is a leading UK cancer research centre. 

ANGLE has now developed the protocols for the Parsortix MK1 machine and GEN3 cassette for the capture of low numbers of cancer cells from whole blood.

Following intensive in-house evaluation, ANGLE is now releasing the Parsortix system to its research partners with delivery of the system anticipated later this week.

The main areas of focus for the first stage of the research partners' work will include:

·     further development of the staining / cell identification protocols to mark the captured cells definitively as cancer cells in the GEN3 cassette;

·     testing of the system with cancer patient blood to provide independent confirmation of the performance of the Parsortix device. 

Following confirmation from our research partners that the system is working successfully, we expect to be able to release a product for research purposes for sale early in the New Year.

ANGLE's Founder and Chief Executive, Andrew Newland, commented:

"Release of the Parsortix system to our research partners is a major step towards our objective of getting a Parsortix product in the market as soon as possible."

For further information:

ANGLE plc	01483 685830
Andrew Newland, Chief Executive Ian Griffiths, Finance Director
Cenkos Securities Stephen Keys, Adrian Hargrave (Nominated adviser) Andy Roberts, Christian Hobart (Sales)	020 7397 8900
Buchanan Mark Court, Fiona Henson, Sophie Cowles	020 7466 5000

 

END

 

 

MSCGGGMPPUPPPPM